Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPPER: Neoadjuvant Endocrine Treatment in HR+/HER2- Breast Cancer
NCT06361940Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tamoxifen in breast cancer, sponsored by Medical College of Wisconsin. Started Sep 2024; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06361940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361940.